JP7591040B2 - リン酸化タウタンパク質への結合を介した神経障害を検出する方法 - Google Patents

リン酸化タウタンパク質への結合を介した神経障害を検出する方法 Download PDF

Info

Publication number
JP7591040B2
JP7591040B2 JP2022517199A JP2022517199A JP7591040B2 JP 7591040 B2 JP7591040 B2 JP 7591040B2 JP 2022517199 A JP2022517199 A JP 2022517199A JP 2022517199 A JP2022517199 A JP 2022517199A JP 7591040 B2 JP7591040 B2 JP 7591040B2
Authority
JP
Japan
Prior art keywords
carbons
alkyl
heterocycloalkyl
heteroarylene
less carbons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022517199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548158A5 (https=
JP2022548158A (ja
Inventor
ステラ サッラーフ，
スハイル ラスール，
Original Assignee
アミディス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミディス， インコーポレイテッド filed Critical アミディス， インコーポレイテッド
Publication of JP2022548158A publication Critical patent/JP2022548158A/ja
Publication of JP2022548158A5 publication Critical patent/JP2022548158A5/ja
Priority to JP2024172134A priority Critical patent/JP2024177285A/ja
Application granted granted Critical
Publication of JP7591040B2 publication Critical patent/JP7591040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022517199A 2019-09-18 2020-09-17 リン酸化タウタンパク質への結合を介した神経障害を検出する方法 Active JP7591040B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024172134A JP2024177285A (ja) 2019-09-18 2024-10-01 リン酸化タウタンパク質への結合を介した神経障害を検出する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902265P 2019-09-18 2019-09-18
US62/902,265 2019-09-18
PCT/US2020/051325 WO2021055639A1 (en) 2019-09-18 2020-09-17 Methods of detecting neurological disorders via binding to phosphorylated tau protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024172134A Division JP2024177285A (ja) 2019-09-18 2024-10-01 リン酸化タウタンパク質への結合を介した神経障害を検出する方法

Publications (3)

Publication Number Publication Date
JP2022548158A JP2022548158A (ja) 2022-11-16
JP2022548158A5 JP2022548158A5 (https=) 2023-11-13
JP7591040B2 true JP7591040B2 (ja) 2024-11-27

Family

ID=74883484

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517199A Active JP7591040B2 (ja) 2019-09-18 2020-09-17 リン酸化タウタンパク質への結合を介した神経障害を検出する方法
JP2024172134A Pending JP2024177285A (ja) 2019-09-18 2024-10-01 リン酸化タウタンパク質への結合を介した神経障害を検出する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024172134A Pending JP2024177285A (ja) 2019-09-18 2024-10-01 リン酸化タウタンパク質への結合を介した神経障害を検出する方法

Country Status (7)

Country Link
US (1) US20220370642A1 (https=)
EP (1) EP4031879A4 (https=)
JP (2) JP7591040B2 (https=)
CN (1) CN114729945B (https=)
AU (1) AU2020348382A1 (https=)
CA (1) CA3154481A1 (https=)
WO (1) WO2021055639A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52796A (fr) 2018-05-31 2021-04-14 Amydis Inc Compositions et procédés de détection d'une lésion cérébrale traumatique
WO2022266210A1 (en) * 2021-06-16 2022-12-22 The Regents Of The University Of California Amyloid targeting agents and methods of using the same
JP2024525693A (ja) * 2021-07-15 2024-07-12 アミディス， インコーポレイテッド 神経変性障害の診断のためにアミロイドおよびアミロイド様タンパク質を検出するためのフルオロフォアとしてのｎ－ヘテロシクリル置換２－シアノ－３－（ナフタレン－２－イル）アクリルアミド誘導体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040891A2 (en) 2014-09-12 2016-03-17 Amydis Diagnostics In vitro compositions comprising human sample and amyloid targeting agent
JP2017512834A (ja) 2014-03-19 2017-05-25 アミディス・ダイアグノスティックス・インコーポレイテッド アミロイド標的剤及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102115429B (zh) * 2010-01-06 2013-02-27 中国科学院上海药物研究所 (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途
RU2627694C2 (ru) * 2010-10-29 2017-08-10 Клино Лтд. Производные хинолина, визуализирующий белок тау
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
MA52796A (fr) * 2018-05-31 2021-04-14 Amydis Inc Compositions et procédés de détection d'une lésion cérébrale traumatique
AU2019372432B2 (en) * 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017512834A (ja) 2014-03-19 2017-05-25 アミディス・ダイアグノスティックス・インコーポレイテッド アミロイド標的剤及びその使用方法
WO2016040891A2 (en) 2014-09-12 2016-03-17 Amydis Diagnostics In vitro compositions comprising human sample and amyloid targeting agent

Also Published As

Publication number Publication date
WO2021055639A1 (en) 2021-03-25
JP2024177285A (ja) 2024-12-19
AU2020348382A1 (en) 2022-04-28
US20220370642A1 (en) 2022-11-24
JP2022548158A (ja) 2022-11-16
EP4031879A4 (en) 2023-11-15
CA3154481A1 (en) 2021-03-25
CN114729945B (zh) 2025-09-02
EP4031879A1 (en) 2022-07-27
CN114729945A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
JP2024177285A (ja) リン酸化タウタンパク質への結合を介した神経障害を検出する方法
JP7637288B2 (ja) 神経障害を検出するためのリン酸化合物
AU2019201325A1 (en) Amyloid targeting agents and methods of using the same
JP7583895B2 (ja) 外傷性脳損傷を検出するための組成物および方法
CN117916225A (zh) N-杂环基取代的2-氰基-3-(萘-2-基)丙烯酰胺衍生物作为荧光团用于检测类淀粉蛋白和类淀粉样蛋白以诊断神经退行性病症
WO2024155678A1 (en) Amyloid targeting agents
CN121991127A (zh) 用于对神经疾病进行检测的磷酸盐化合物
HK40061967A (en) Phosphate compounds for detecting neurological disorders
HK40061967B (en) Phosphate compounds for detecting neurological disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241115

R150 Certificate of patent or registration of utility model

Ref document number: 7591040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150